Skip to main content
Journal cover image

Pathophysiologic and therapeutic importance of tissue ACE: a consensus report.

Publication ,  Journal Article
Dzau, VJ; Bernstein, K; Celermajer, D; Cohen, J; Dahlöf, B; Deanfield, J; Diez, J; Drexler, H; Ferrari, R; Van Gilst, W; Hansson, L; Hornig, B ...
Published in: Cardiovasc Drugs Ther
March 2002

Angiotensin-converting enzyme (ACE) activation and the de novo production of angiotensin II contribute to cardiovascular disease through direct pathological tissue effects, including vascular remodeling and inflammation, as well as indirect action on nitric oxide bioavailability and its consequences. The endothelium plays a pivotal role in both vascular function and structure; thus, the predominant localization of ACE to the endothelium has implications for the pathobiology of vascular disease, such as coronary artery disease. Numerous experimental studies and clinical trials support the emerging realization that tissue ACE is a vital therapeutic target, and that its inhibition may restore endothelial function or prevent endothelial dysfunction. These effects exceed those attributable to blood pressure reduction alone; hence, ACE inhibitors may exert an important part of their effects through direct tissue action. Pharmacologic studies show that while ACE inhibitors may differ according to their binding affinity for tissue ACE the clinical significance remains to be determined.

Duke Scholars

Published In

Cardiovasc Drugs Ther

DOI

ISSN

0920-3206

Publication Date

March 2002

Volume

16

Issue

2

Start / End Page

149 / 160

Location

United States

Related Subject Headings

  • Serine Endopeptidases
  • Renin-Angiotensin System
  • Peptidyl-Dipeptidase A
  • Organ Specificity
  • Nitric Oxide
  • Humans
  • Fibrinolysis
  • Clinical Trials as Topic
  • Chymases
  • Cardiovascular System & Hematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dzau, V. J., Bernstein, K., Celermajer, D., Cohen, J., Dahlöf, B., Deanfield, J., … Weber, M. (2002). Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther, 16(2), 149–160. https://doi.org/10.1023/a:1015709617405
Dzau, Victor J., Kenneth Bernstein, David Celermajer, Jerome Cohen, Björn Dahlöf, John Deanfield, Javier Diez, et al. “Pathophysiologic and therapeutic importance of tissue ACE: a consensus report.Cardiovasc Drugs Ther 16, no. 2 (March 2002): 149–60. https://doi.org/10.1023/a:1015709617405.
Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlöf B, Deanfield J, et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther. 2002 Mar;16(2):149–60.
Dzau, Victor J., et al. “Pathophysiologic and therapeutic importance of tissue ACE: a consensus report.Cardiovasc Drugs Ther, vol. 16, no. 2, Mar. 2002, pp. 149–60. Pubmed, doi:10.1023/a:1015709617405.
Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlöf B, Deanfield J, Diez J, Drexler H, Ferrari R, Van Gilst W, Hansson L, Hornig B, Husain A, Johnston C, Lazar H, Lonn E, Lüscher T, Mancini J, Mimran A, Pepine C, Rabelink T, Remme W, Ruilope L, Ruzicka M, Schunkert H, Swedberg K, Unger T, Vaughan D, Weber M. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther. 2002 Mar;16(2):149–160.
Journal cover image

Published In

Cardiovasc Drugs Ther

DOI

ISSN

0920-3206

Publication Date

March 2002

Volume

16

Issue

2

Start / End Page

149 / 160

Location

United States

Related Subject Headings

  • Serine Endopeptidases
  • Renin-Angiotensin System
  • Peptidyl-Dipeptidase A
  • Organ Specificity
  • Nitric Oxide
  • Humans
  • Fibrinolysis
  • Clinical Trials as Topic
  • Chymases
  • Cardiovascular System & Hematology